{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:57:13Z","timestamp":1793105833349,"version":"4.5.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Platelet factor 4 (PF4), also known as chemokine (C-X-C motif) ligand 4 (CXCL4), is a specific protein synthesized from platelet \u03b1 particles. The combination of PF4 and heparin to form antigenic complexes is an important mechanism in the pathogenesis of heparin-induced thrombocytopenia (HIT), but vaccine-induced immune thrombotic thrombocytopenia (VITT) related to the COVID-19 vaccine makes PF4 a research hotspot again. Similar to HIT, vaccines, bacteria, and other non-heparin exposure, PF4 can interact with negatively charged polyanions to form immune complexes and participate in thrombosis. These anions include cell surface mucopolysaccharides, platelet polyphosphates, DNA from endothelial cells, or von Willebrand factor (VWF). Among them, PF4\u2013VWF, as a new immune complex, may induce and promote the formation of immune-associated thrombosis and is expected to become a new target and therapeutic direction. For both HIT and VITT, there is no effective and targeted treatment except discontinuation of suspected drugs. The research and development of targeted drugs based on the mechanism of action have become an unmet clinical need. Here, this study systematically reviewed the characteristics and pathophysiological mechanisms of PF4 and VWF, elaborated the potential mechanism of action of PF4\u2013VWF complex in immune-associated thrombosis, summarized the current status of new drug research and development for PF4 and VWF, and discussed the possibility of this complex as a potential biomarker for early immune-associated thrombosis events. Moreover, the key points of basic research and clinical evaluation are put forward in the study.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1098665","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T04:40:46Z","timestamp":1677559246000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhi-Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Xue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Qi","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1411910","article-title":"Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood.2021012217","article-title":"Frequency of positive anti-PF4\/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"138","author":"Thiele","year":"2021","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1084\/jem.154.1.88","article-title":"Expression of platelet proteins in early marrow megakaryocytes","volume":"154","author":"Rabellino","year":"1981","journal-title":"J Exp Med"},{"key":"B5","article-title":"Biochemistry of alpha granule proteins","volume":"22","author":"Holt","year":"1985","journal-title":"Semin Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2008.05267.x","article-title":"Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3","volume":"105","author":"de Jong","year":"2008","journal-title":"J Neurochem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(80)90431-4","article-title":"Human platelet factor 4 and tissue mast cells","volume":"19","author":"McLaren","year":"1980","journal-title":"Thromb Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/2221269a0","article-title":"Platelet factor 4 and adenosine diphosphate release during human platelet aggregation","volume":"222","author":"Niewiarowski","year":"1969","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V53.4.604.604","article-title":"Platelet alpha-granule proteins: studies on release and subcellular localization","volume":"53","author":"Kaplan","year":"1979","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0105024","article-title":"Regulated expression of platelet factor 4 in human monocytes\u2013role of PARs as a quantitatively important monocyte activation pathway","volume":"78","author":"Schaffner","year":"2005","journal-title":"J Leukoc Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052035","article-title":"PF-4\/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion","volume":"109","author":"Lasagni","year":"2007","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2022.02.005","article-title":"Platelet-activating anti-PF4 disorders: An overview","volume":"59","author":"Warkentin","year":"2022","journal-title":"Semin Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.01.006","article-title":"Platelet factor-4 (CXCL4\/PF-4): an angiostatic chemokine for cancer therapy","volume":"331","author":"Wang","year":"2013","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.1.219.219","article-title":"Cloning and characterization of platelet factor 4 cDNA derived from a human erythroleukemic cell line","volume":"69","author":"Poncz","year":"1987","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.6.2256","article-title":"Amino acid sequence of human platelet factor 4","volume":"74","author":"Deuel","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/bi00450a034","article-title":"Human platelet factor 4 monomer-dimer-tetramer equilibria investigated by 1H NMR spectroscopy","volume":"28","author":"Mayo","year":"1989","journal-title":"Biochemistry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2004.12.003","article-title":"Platelet factor 4: a chemokine enigma","volume":"37","author":"Slungaard","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-831048","article-title":"Interactions of platelet factor 4 with the vessel wall","volume":"30","author":"Sachais","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"Greinacher","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.08.002","article-title":"Potential mechanisms of vaccine-induced thrombosis","volume":"105","author":"Marietta","year":"2022","journal-title":"Eur J Intern Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00306-9","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"9","author":"Klok","year":"2022","journal-title":"Lancet Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2020.04.014","article-title":"Pathogenesis of heparin-induced thrombocytopenia","volume":"225","author":"Arepally","year":"2020","journal-title":"Transl Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-292938","article-title":"Heparin modifies the immunogenicity of positively charged proteins","volume":"116","author":"Chudasama","year":"2010","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)47284-5","article-title":"Platelet factor 4 stimulates thrombomodulin protein c-activating cofactor activity. a structure-function analysis","volume":"269","author":"Slungaard","year":"1994","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3529","article-title":"Platelet factor 4 enhances generation of activated protein c in vitro and in vivo","volume":"102","author":"Slungaard","year":"2003","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2009.11.023","article-title":"Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis","volume":"125","author":"Kowalska","year":"2010","journal-title":"Thromb Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111429","article-title":"Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium","volume":"74","author":"Marcum","year":"1984","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(85)90033-9","article-title":"Interaction of platelet factor 4 with human platelets","volume":"839","author":"Capitanio","year":"1985","journal-title":"Biochim Biophys Acta"},{"key":"B30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1471-2407-11-261","article-title":"Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo","volume":"11","author":"Yang","year":"2011","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.9.3289","article-title":"Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization","volume":"91","author":"Perollet","year":"1998","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.9.3087","article-title":"Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway","volume":"100","author":"Sulpice","year":"2002","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.2004.04263.x","article-title":"Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms","volume":"271","author":"Sulpice","year":"2004","journal-title":"Eur J Biochem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1756-8722-6-42","article-title":"Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology","volume":"6","author":"Pilatova","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00459","article-title":"Neuro-immune hemostasis: Homeostasis and diseases in the central nervous system","volume":"12","author":"De Luca","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3613","article-title":"Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface","volume":"99","author":"Sachais","year":"2002","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255450","article-title":"Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera","volume":"36","author":"Lippi","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.7.4584","article-title":"Platelet factor 4 is chemotactic for neutrophils and monocytes","volume":"78","author":"Deuel","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.72.3.590","article-title":"Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8","volume":"72","author":"Marti","year":"2002","journal-title":"J Leukoc Biol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"106098","DOI":"10.1016\/j.rmed.2020.106098","article-title":"Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy","volume":"171","author":"Mallah","year":"2020","journal-title":"Respir Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2304-3881.2015.06.08","article-title":"Pancreatic cancer and thromboembolic disease, 150 years after trousseau","volume":"4","author":"Ansari","year":"2015","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/jcpe.12771","article-title":"Chronic periodontitis is associated with platelet factor 4 (PF4) secretion: A pilot study","volume":"44","author":"Brousseau-Nault","year":"2017","journal-title":"J Clin Periodontol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.05.002","article-title":"Increased platelet factor 4 and aberrant permeability of follicular fluid in PCOS","volume":"118","author":"Huang","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-015-0348-x","article-title":"Low levels of circulating platelet factor 4 (PF4, CXCL4) in subclinically hypothyroid autoimmune thyroiditis","volume":"39","author":"G\u00f6rar","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0085-5","article-title":"Von Willebrand factor and thrombosis","volume":"85","author":"Franchini","year":"2006","journal-title":"Ann Hematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1041-x","article-title":"Von willebrand factor: at the crossroads of bleeding and thrombosis","volume":"95","author":"Denis","year":"2012","journal-title":"Int J Hematol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/5584_2016_122","article-title":"Thrombosis and von willebrand factor","volume":"906","author":"Shahidi","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2516.2008.01848.x","article-title":"Function of von willebrand factor in haemostasis and thrombosis","author":"Reininger","year":"2008","journal-title":"Haemophilia"},{"key":"B49","first-page":"94","article-title":"Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman","year":"2003","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16553","article-title":"Platelet factor 4 inhibits ADAMTS13 activity and regulates the multimeric distribution of von willebrand factor","volume":"190","author":"Nazy","year":"2020","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018881607","article-title":"Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation","volume":"135","author":"Johnston","year":"2020","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/bjh.18145","article-title":"Wi, platelet degranulation and bleeding phenotype in a large cohort of Von willebrand disease patients","volume":"197","author":"Swinkels","year":"2022","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12581","article-title":"Low ADAMTS-13 predicts adverse outcomes in hospitalized patients with suspected heparin-induced thrombocytopenia","volume":"5","author":"Chan","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15830","article-title":"Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction","volume":"20","author":"Fogarty","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30216-7","article-title":"Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study","volume":"7","author":"Goshua","year":"2020","journal-title":"Lancet Haematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.3390\/cells10102785","article-title":"Shedding light on the possible link between ADAMTS13 and vaccine-induced thrombotic thrombocytopenia","volume":"10","author":"Szostek-Mioduchowska","year":"2021","journal-title":"Cells"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12511","article-title":"Effect of ADAMTS-13 on cerebrovascular microthrombosis and neuronal injury after experimental subarachnoid hemorrhage","volume":"12","author":"Muroi","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B59","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1098665\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T04:40:50Z","timestamp":1677559250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1098665\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2023.1098665"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1098665","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"article-number":"1098665"}}